Oxford–AstraZeneca COVID-19 vaccine

Oxford–AstraZeneca COVID-19 vaccine. It is a viral vector vaccine for the prevention of COVID-19 developed by the University of Oxford and the British-Swedish company AstraZeneca. The vaccine, also known as Vaxzevria and Covishield, was a critical tool in the global response to the COVID-19 pandemic, with billions of doses produced. It was widely used globally, particularly through the COVAX initiative, due to its relatively low cost and ease of storage compared to some mRNA vaccines.

Development and authorization

The vaccine's development was led by the Jenner Institute and the Oxford Vaccine Group at the University of Oxford, with key researchers including Sarah Gilbert, Andrew Pollard, and Teresa Lambe. A pivotal partnership was formed with AstraZeneca in April 2020 for global development and manufacturing. The first regulatory authorization for emergency use was granted by the United Kingdom in December 2020, following a positive review by the Medicines and Healthcare products Regulatory Agency. This was quickly followed by authorizations from the European Medicines Agency and the World Health Organization in early 2021. Notably, a large-scale manufacturing and distribution agreement was also established with the Serum Institute of India, which produced the vaccine under the name Covishield for use in India and many other countries.

Technology

The vaccine utilizes a non-replicating viral vector platform, employing a modified version of a chimpanzee adenovirus known as ChAdOx1. This vector is engineered to be incapable of replication in human cells and is used as a carrier to deliver the genetic sequence for the SARS-CoV-2 spike protein. Once administered, the body's cells use this genetic code to temporarily produce the spike protein, triggering an immune response that generates antibodies and primes T cells. This technology had a foundation in prior work by the University of Oxford on vaccines for diseases like Middle East respiratory syndrome and Ebola virus disease.

Efficacy and clinical trials

Primary efficacy data came from large-scale Phase III trials conducted across multiple countries, including the United Kingdom, Brazil, and South Africa. Published results in The Lancet in December 2020 indicated an average efficacy of approximately 70% in preventing symptomatic COVID-19, with higher efficacy observed with a longer interval between doses. Subsequent real-world studies by Public Health England and other agencies confirmed high effectiveness against severe disease, hospitalization, and death, particularly from variants like the Alpha variant. Research also demonstrated that the vaccine could be used effectively in heterologous prime-boost regimens, such as following a first dose of the Pfizer–BioNTech COVID-19 vaccine.

Manufacturing and distribution

AstraZeneca established a vast global supply network with over 25 manufacturing facilities in 15 countries, including partnerships with the Serum Institute of India, SK Bioscience in South Korea, and the Halix plant in the Netherlands. The vaccine was central to the COVAX facility, co-led by Gavi, the Vaccine Alliance, the World Health Organization, and the Coalition for Epidemic Preparedness Innovations, which aimed for equitable global distribution. Its simpler storage requirements, stable at refrigerator temperatures, made it logistically easier to deploy in low-resource settings compared to Moderna or Pfizer–BioNTech COVID-19 vaccines.

Adverse events and controversies

In early 2021, reports emerged linking the vaccine to a rare but serious condition involving blood clots with low platelets, termed thrombosis with thrombocytopenia syndrome. Regulatory agencies like the European Medicines Agency and the Medicines and Healthcare products Regulatory Agency confirmed the link while emphasizing that the benefits outweighed the risks. This led to usage restrictions in some countries, such as Germany and Denmark, for certain age groups. Other controversies involved disputes over European Union contract fulfillment and supply delays, and a temporary suspension of use in several countries during the safety review. The vaccine was also subject to disinformation campaigns and geopolitical tensions during the COVID-19 pandemic. Category:COVID-19 vaccines Category:AstraZeneca Category:University of Oxford